Advertisement

Topics

Seattle Genetics gets FDA priority review for Adcetris in Cutaneous T-Cell Lymphoma

05:22 EDT 17 Aug 2017 | Pharmaceutical Business Review

Seattle Genetics reported that the US Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the phase 3 ALCANZA trial and two phase 2 trials of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).

Original Article: Seattle Genetics gets FDA priority review for Adcetris in Cutaneous T-Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics gets FDA priority review for Adcetris in Cutaneous T-Cell Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...